HCW Biologics Inc. Long-Term Debt, Maturity, Year One
HCW Biologics Inc. (HCWB) had Long-Term Debt, Maturity, Year One of $119.40 thousand as of 2023-12-31, per its 10-K/A filed 2024-05-15.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2024-05-15
- 2023-12-31: Long-Term Debt, Maturity, Year One $119.40K.
- 2022-12-31: Long-Term Debt, Maturity, Year One $38.27K.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2023-12-31 | $119.40K 10-K/A · filed 2024-05-15 |
| 2022-12-31 | $38.27K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |